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A B S T R A C T
Background
The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown.
Methods and Findings
In a prospective study conducted between August 1992 and December 2002, 260 apparently
healthy individuals with incidentally discovered platelet counts between 1003 109/l and 1503
109/l were monitored for 6 mo to determine whether their condition persisted. The monitoring
period was completed in 217 cases, of whom 191 (88%) maintained stable platelet counts.
These 191 individuals were included in a long-term follow-up study to gain knowledge of their
natural history. With a median time of observation of 64 mo, the thrombocytopenia resolved
spontaneously or persisted with no other disorders becoming apparent in 64% of cases. The
most frequent event during the study period was the subsequent development of an
autoimmune disease. The 10-y probability of developing idiopathic thrombocytopenic purpura
(ITP), as defined by platelet counts persistently below 1003 109/l, was 6.9% (95% confidence
interval [CI]: 4.0%–12.0%). The 10-y probability of developing autoimmune disorders other than
ITP was 12.0% (95% CI: 6.9%–20.8%). Most of the cases (85%) of autoimmune disease occurred
in women.
Conclusions
Healthy individuals with a sustained platelet count between 1003109/l and 1503109/l have
a 10-y probability of developing autoimmune disorders of 12%. Further investigation is
required to establish whether this risk is higher than in the general population and whether an
intensive follow-up results in an improvement of prognosis.
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Introduction
With extensive automation in laboratories, an ever
increasing number of asymptomatic individuals with platelet
counts ranging between 100 3 109/l and 150 3 109/l are now
being recognized [1–3]. However, both the clinical features of
these individuals, as well as the natural history of their
thrombocytopenia, have not been systematically studied. An
undetermined number may go on to develop an overt disease
associated with a low platelet count, others may maintain
normal or borderline platelet counts indeﬁnitely, but to date
no consistent ﬁgures concerning these events are available.
Although the differential diagnosis is fairly broad, most
asymptomatic adults who have a low platelet count as the sole
laboratory abnormality are likely to have an immune
thrombocytopenia, either primary (idiopathic) or secondary
to an autoimmune disorder [4]. In fact, thrombocytopenia
may often be the initial manifestation of a systemic auto-
immune disease; thus, it may not be possible to differentiate
secondary immune thrombocytopenia at the time of initial
presentation from idiopathic thrombocytopenic purpura
(ITP). Information about these patients has a potential
clinical impact because many systemic autoimmune diseases
can be treated and controlled if detected in the early stages.
Patients often have symptoms for several years before the
correct diagnosis is made, and this delay in treatment may
cause damage to major organs and result in permanent
disability [5].
This study was designed with the aim of elucidating the
natural history of apparently healthy adults who were
diagnosed with a platelet count between 100 3 109/l and
150 3 109/l, cases that in this study were deﬁned as having
‘‘borderline thrombocytopenia.’’
Methods
Patient Selection
This study was conducted prospectively between August
1992 and December 2002 and included a consecutive series of
apparently healthy individuals who were referred to the
outpatient clinics of the Department of Hematology of the
University of Rome ‘‘Tor Vergata’’ and the Department of
Medical Sciences of Ospedale ‘‘Regina Apostolorum’’ in
Albano Laziale, Rome, because they had been found with a
platelet count between 1003 109/l and 1503 109/l. Together,
these two tertiary health-care centers serve a population of
approximately 600,000 people in the southeast region of
Rome and its surroundings. To be considered ‘‘apparently
healthy,’’ such individuals had to be free of a history of
chronic medical disorders such as hypertension, autoimmune
disorders, liver diseases, and malignancies previously treated
with chemotherapy or radiotherapy, and were not currently
on medication or had not taken any medication in the last 3
mo; pregnancy had to be excluded in premenopausal women.
Medical conditions that did not preclude inclusion in the
study were iron-deﬁciency anemia (in menstruating women),
thalassemia trait, and osteoarthritis.
In addition to obtaining a detailed clinical history, the
initial evaluation of these patients included a physical
examination and a complete blood count. The platelet count
was determined using electronic analyzers, and was always
conﬁrmed by direct observation of peripheral blood smears.
Additional laboratory tests included routine serum chemistry
(renal and liver function, bone biochemistry), serum protein
electrophoresis, antinuclear antibodies (ANA), antithyroper-
oxidase antibodies (TPO-Ab), anticardiolipin antibodies
(ACA), screening for hepatitis B and C infection, screening
for human immunodeﬁciency virus (HIV) infection, and
rheumatoid factor. Ultrasound scans were performed in very
obese people, in whom physical examination could not
reliably exclude splenomegaly, as well as in those with
positive ANA or rheumatoid factor.
Study Design
Eligible patients were monitored for 6 mo with monthly
visits, and if they maintained their platelet count between 100
3 109/l and 150 3 109/l, they were classiﬁed as ‘‘borderline
thrombocytopenia.’’ Observation of these cases after the ﬁrst
6 mo was scheduled every 3 mo for the ﬁrst 2 y, and every 6
mo thereafter, unless there were clinical indications for more
frequent visits. A complete blood count and clinical evalua-
tion were performed at each visit.
It has been shown that autoantibodies are typically present
many years before the diagnosis of an autoimmune disease is
made [6,7]. To rule out the possibility that our study cohort
was not a selected high-risk subset relative to the general
population, we compared the autoantibody proﬁle of these
individuals with that of a control group. This control group
comprised healthy individuals with platelet counts in excess
of 1503 109/l, matched by sex and age (62 y) to individuals of
the study cohort (three controls for each individual of the
study cohort). The control group was extracted from a larger
sample of approximately 62,000 individuals in a population-
based survey of metabolic disorders which had aimed to
deﬁne the prevalence of diabetes, dyslipidemia, and hyper-
uricemia in the local population. An institutional review
board–approved informed consent was obtained for both the
study cohort and controls.
Statistical Methods
Statistical analysis was carried out using the NCSS software
package (NCSS, Kaysville, Utah, United States). The statistical
signiﬁcance of differences was evaluated by the chi-square
test for categorical variables, whereas Student’s t-test was used
for continuous variables. A p-value of 0.05 or less was deemed
to be statistically signiﬁcant. The probability of developing
either ITP or an autoimmune disease over time was estimated
by the cumulative incidence procedure. Cumulative inci-
dence, also referred to as competing risk analysis, is an
extension of the Kaplan–Meier survival technique to the case
where failure occurs for several reasons [8,9]. The Kaplan–
Meier approach provides a nonparametric estimate of the
overall survival probability of an event of interest, but ignores
the presence of competing risks. In contrast, the cumulative
incidence estimates the percentage of patients who will be
diagnosed with the event of interest in a certain time interval
in the presence of competing risks. In our case, the event of
interest was the development of either ITP or an autoimmune
disease, and competing causes were considered: lost to follow-
up (including cases who had achieved a sustained normal
platelet count), death, development of either an autoimmune
disease (when the cumulative incidence of ITP was estimated)
or of ITP (when the cumulative incidence of an autoimmune
disease was estimated), and development of other diseases
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(cardiovascular diseases, malignancies, or myelodysplastic
syndromes).
The effect of the presence of autoimmune markers on the
risk of developing autoimmune disorders was estimated by
proportional hazards regression analysis.
The analysis was based on follow-up information obtained
through November 30, 2004.
Results
Study Cohort Characteristics
Five-hundred twenty-seven individuals with a platelet
count between 100 3 109/l and 150 3 109/l and no other
hematologic abnormalities apart from iron-deﬁciency ane-
mia (in menstruating women) or thalassemia trait were seen
in our outpatient clinics during the study period. Two
hundred ﬁfty-four were receiving continuous medication
that could not be discontinued or had a history of malignancy
or chronic inﬂammatory disorder, and were excluded from
this study. Of the remaining 273, 13 were also excluded for
the following reasons: Three tested positive for hepatitis C
virus, one was a chronic carrier of hepatitis B surface antigen,
ﬁve had hypothyroidism associated with high titers of TPO-
Ab, and ﬁve were diagnosed with Sjo¨gren’s Syndrome.
Markers of autoimmunity in the absence of other clinical
or laboratory abnormalities suggestive of an autoimmune
disorder were found in 37 (14.2 %) cases. These individuals, as
well as 223 others who had no laboratory abnormality, were
considered eligible for the study. Thus, we began the 6-mo
monitoring phase in 260 individuals (107 men and 153
women; median age 52 y, range 15–82 y). The study design
and results are summarized in Figure 1.
Initial 6-mo Observation
The initial monitoring period of 6 mo was completed in
217 (83.4%) of 260 cases. The 43 participants who did not
complete this phase communicated their withdrawal from the
study with refusal to undergo medical assessments. Their
clinical characteristics did not differ signiﬁcantly from those
of the patients who actually completed the initial follow-up
(Table 1).
Among those who completed this initial observation
period, a 73-y-old woman and a 69-y-old man had worsening
thrombocytopenia with subsequent development of anemia.
They were diagnosed with a myelodysplastic syndrome
(refractory anemia) after 3 and 5 mo of observation,
respectively. A 32-y-old woman who tested positive for both
ANA and ACA developed hypertension and renal function
abnormalities, and was diagnosed with systemic lupus
erythematosus after 5 mo of observation. The other individ-
uals had a variable pattern of their platelet counts (Table 2).
There were no signiﬁcant differences in terms of gender, age,
autoimmune proﬁle, or baseline platelet count between these
various groups of individuals.
A normal count that had been maintained for at least 3 mo
was achieved by 23 individuals. Although these cases were
followed for three more months to conﬁrm the stability of the
platelet count, they were considered ineligible for the follow
up study. In 11 individuals, platelet counts fell below 100 3
109/l for at least 3 mo. In one case, the platelet count reached
values as low as 333 109/l. Nadir values for the other cases of
this subset were between 47 3 109/l and 83 3 109/l. Bone
Figure 1. Study Design and Results
DOI: 10.1371/journal.pmed.0030024.g001
Table 1. Comparisons of Clinical Characteristics between
Individuals Who Completed the Observation Phase and Those
Who Withdrew from Study before 6 mo
Characteristic Complete
Observation
Incomplete
Observation
p-Value
Number of cases
Men 92 15
Women 125 28 0.36
Age (y)
Median 52 51
Range 18–82 15–77 0.47a
Platelet count (3 109/l)
Median 127 120
Range 101–148 104–148 0.70b
ACA
Positive 28 6
Negative 189 37 0.85
a95% CI for t-test differences:3.30, 7.05.
b95% CI for t-test differences: 3.75, 5.50.
DOI: 10.1371/journal.pmed.0030024.t001
Table 2. Behavior of the Platelet Counts during the Initial 6-mo
Monitoring Phase in 214 Individuals Who Completed the
Observation
Platelet Count Number of Cases
Stably between 100–150 3 109/la 87 (41%)
Stably above 150 3 109/lb 23 (11%)
Sporadically above 150 3 109/lc 39 (18%)
Sporadically below 150 3 109/lc 54 (25%)
Stably below 100 3 109/lb 11 (5%)
aThroughout the 6 mo.
bValues recorded at last visit, and had to be maintained for at least 3 mo.
cLess than 3-mo duration.
DOI: 10.1371/journal.pmed.0030024.t002
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marrow examination was performed in all of these patients to
exclude myelodysplasia or other hematologic disorders.
These cases were classiﬁed by default as ITP, but continued
the observational study.
Follow-Up
A total of 191 individuals with a conﬁrmed borderline
thrombocytopenia entered the follow-up study. Their base-
line clinical and laboratory characteristics are reported in
Table 3.
In the control group, markers of autoimmunity were found
in 70/573 (12.3%) individuals, a prevalence similar to that of
the study cohort (13.6%; p ¼ 0.614). Speciﬁcally, in controls,
ACA were found in 46 cases (8.1%), high titers of TPO-Ab
were detected in 36 (6.2%), ANA was positive in 16 (2.8%),
and ﬁve had high levels of rheumatoid factor (0.9%).
Table 4 summarizes the outcome of individuals with
borderline thrombocytopenia. The overall median follow-up
duration was 64 mo (range 6–140 mo). Twenty-six individuals
were lost to follow-up while their counts were stable above
100 3 109/l. The median follow-up duration for these cases
was 45.5 mo (range 14–124 mo). Median follow-up duration
from the date of accrual for the remaining 165 cases with
complete observation was 67 mo (range 6–140 mo).
Thirteen individuals achieved stable (.6 mo) platelet
counts above 150 3 109/l. There was no association between
the baseline platelet count and the probability of achieving a
normal platelet count. One hundred nine individuals were
considered to have a stable borderline thrombocytopenia.
Although 93 of these individuals experienced ﬂuctuations of
their platelet counts below 100 3 109/l, the duration of
signiﬁcant thrombocytopenia was never in excess of 4 mo.
Five of the 11 patients classiﬁed as having ITP after the
initial 6-mo observation developed an autoimmune disease.
Therefore, these cases were reclassiﬁed. Platelet counts below
1003109/l developed in six other cases at 6 to 62 mo from the
start of the study, with nadir values ranging from 14 to 653
109/l. A bone marrow aspirate was performed in all these
individuals, and was consistent with a diagnosis of having ITP.
In total, at the end of the study, 12 cases met our deﬁnition of
ITP, and the probability of developing ITP at 10 y was 6.9%
(95% conﬁdence interval [CI]: 4.0%–12.0%) (Figure 2).
An autoimmune disorder developed in 13 cases at 29 to 110
mo from the start of the study. Clinical symptoms were the
cause that led 12 of these 13 participants to be further
investigated for the underlying autoimmune disorder. In only
one case (woman, age 72 y) was there the ﬁnding of abnormal
liver function tests, in the absence of symptoms, which led to
further investigation that resulted in the diagnosis of primary
biliary cirrhosis. The detailed features for these individuals
are reported in Table 5. It is noteworthy that in seven cases,
markers of autoimmunity were present at the time they began
follow-up.
The probability of developing autoimmune disorders other
than ITP at 10 y was 12.0% (95% CI: 6.9%–20.8%) (Figure 3).
The probability of developing autoimmune disorders among
individuals who presented with autoimmune markers on
study entry was 7.2% (95% CI: 4.0%–12.9%), and 4.7% (95%
CI: 0.7%–12.2%) in those who had negative markers, with a
hazard ratio of 2.78 (95% CI: 0.71–8.54; p ¼ 0.117).
Ischemic heart disease developed in six patients (four men
and two women, median age 71.5 y) at 29 to 77 mo during
follow-up. None of these patients had laboratory abnormal-
ities consistent with an autoimmune disease.
Table 3. Characteristics of Individuals with Borderline Throm-
bocytopenia Who Began Follow-Up
Characteristic Value
Number of Cases 191
Men 81
Women 110
Age
Median 53 y
Range 17–82 y
Baseline platelet count (3 109/l)
Median 126 3 109/l
Range 101–148 3 109/l
Distribution of cases in relation to platelet counts
101–110 3 109/l 44 (23%)
111–120 3 109/l 30 (16%)
121–130 3 109/l 45 (24%)
131–140 3 109/l 47 (24%)
141–148 3 109/l 25 (13%)
ACAþ 19 (9.9%)
TPOAbþ 13 (6.8%)
ANAþ 8 (4.1%)
ANAþ/ACAþ 2 (1.0%)
Rheumatoid factor positive 2 (1.0%)
Positive for any marker of autoimmunity 26 (13.6%)
A plus sign (þ) indicates a positive result.
DOI: 10.1371/journal.pmed.0030024.t003
Table 4. Outcome of Individuals with Borderline Thrombocytopenia Followed after the Initial 6-mo Observation Period
Number of Cases M/F Median Age,
y (range)
Median Follow-up
Duration, mo (range)
Outcome
26 16/10 57.5 (24–80) 45.5 (14–124) Lost to follow-up with platelet counts stably .100 3 109/l
13 5/8 39 (19–66) 59 (28–121) Stable normal platelet counts
109 42/67 48 (17–79) 71 (27–140) Stable borderline thrombocytopenia
12 5/7 48.5 (18–78) 14 (6–62) ITP
13 2/11 45 (20–72) 63 (29–110) Other autoimmune diseases
12 8/4 69.5 (50–82) 75 (29–126) Other diseases
6 3/3 69.5 (62–78) 103.5 (46–118) Died of cardiovascular accidents
F, female; M, male.
DOI: 10.1371/journal.pmed.0030024.t004
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A malignancy was diagnosed in six cases: myelodysplasia
(refractory anemia) in one patient, breast cancer in two,
colorectal cancer in one, and lung cancer in one. Finally, six
additional individuals died. All deaths were attributed to
cardiovascular accidents, but we were unable to obtain the
details for these events.
Discussion
In this study, 191 apparently healthy individuals with
platelet counts stably between 1003 109/l and 1503 109/l for
at least 6 mo were observed in order to determine their long-
term outcome. The design of this study was stimulated by the
paucity of data concerning the natural history of such
individuals. It was particularly interesting to ascertain
whether this condition represents a mild form of immune
thrombocytopenia, either primary (idiopathic) or secondary
to another autoimmune disorder that may manifest over time.
The methodology of the study deserves a few consider-
ations. Although this was a prospective study involving a
consecutive series of individuals, these cases probably
represent only a small fraction of all cases in the areas served
by our hospitals, which had incidentally discovered mild
thrombocytopenia. In fact, many of these cases may not be
referred to a hematologist. However, it would have been
virtually impossible to include primary-care ofﬁces to capture
all abnormal platelet counts in the region. The same issues of
difﬁcult practical approach apply to the follow-up of
individuals in the control group. We are aware that follow-
up of the control group would have been interesting to assess
the relative importance of the follow-up observations in the
study group. Unfortunately, attempts to involve healthy
individuals to undergo long-term periodic medical assess-
ment met with failure. Finally, the fact that individuals were
only included if they were not currently on medication or had
not taken any medication in the last 3 mo would appear to
exclude the majority of elderly individuals. Nevertheless, we
believe this is also one of the strengths of the study, which
tried to eliminate all possible confounding factors. The
dropout rate was 14%, which is perhaps not unexpected
given the length of the study and the above cited reluctance
of many healthy individuals to undergo medical assessment.
Interestingly, in the highly selected cohort of individuals
that began the monitoring phase, a single borderline count
was predictive of sustained borderline thrombocytopenia in
191 (88%) cases. Stably normal platelet counts were even-
tually achieved by 36 participants (14%), the majority of
whom (23/36) improved their counts during the initial 6-mo
observation period. This lends support to the hypothesis that
these cases may have suffered from a ‘‘silent’’ viral infection
or a minor insult of a different nature to the bone marrow.
Figure 2. Cumulative Incidence of ITP
The upper and lower lines indicate the 95% confidence limits.
DOI: 10.1371/journal.pmed.0030024.g002
Table 5. Clinical and Laboratory Characteristics of the 13 Individuals Who Developed an Autoimmune Disease during Follow-Up
Case
Number
Agea/
Sex
Markers of Autoimmunity at Presentation Baseline
Platelet
Countb
Autoimmune Disease Platelet Count
at the Time
of Autoimmune
Disease Diagnosis
Follow-Up
Duration (mo)
ANA ACA
PAIg
Levels TPO-Ab RF Any
36 20/F þ þ High Low Low þ 109 Antiphospholipid antibody syndrome 84 110
44 43/F   Low Low Low  141 Psoriatic arthritis 126 105
52 38/F  þ ND Low Low þ 140 Systemic sclerosis 113 101
65 36/F þ  High High Low þ 104 Systemic lupus erythematosus 69 95
77 45/F   ND High High þ 105 Rheumatoid arthritis 91 91
123 33/F   Low Low Low  143 Inflammatory bowel disease 119 70
135 28/F  þ ND Low High þ 103 Leucocytoclastic vasculitis 69 63
144 38/M   ND Low Low  131 Ankylosing spondylitis 92 59
170 55/F  þ Low High Low þ 124 Inflammatory bowel disease 75 52
178 57/F   Low Low Low  140 Wegener granulomatosis 29 49
182 63/F   High Low Low þ 146 Rheumatoid arthritis 61 47
196 57/M   ND Low Low  108 Acquired hemophilia 83 42
243 72/F   ND Low Low  137 Primary biliary cirrhosis 42 29
aAge is given in years.
bCounts are3 109.
A plus sign (þ) indicates a positive condition; a minus sign () indicates a negative result.
F, female; M, male; ND, not determined; PAIg, platelet-associated immunoglobulin; RF, rheumatoid factor.
DOI: 10.1371/journal.pmed.0030024.t005
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Another possibility is the seasonal variation of the platelet
count that has been described in several reports [10–12].
Finally, since our study cohort is supposed to be an extreme
sample relative to the general population, it is possible that
their initial low values regressed towards their real higher
mean platelet levels [13]. However, in most cases the
thrombocytopenia persisted without other disorders becom-
ing apparent, suggesting that they may simply represent a
part of the left tail of the platelet count distribution observed
in healthy individuals [1–3].
Although debatable, our criteria for designating a case as
ITP (platelet counts ,1003 109/l) have been already used to
determine the incidence of ITP in adults [14], and several
authors have applied the deﬁnition of ‘‘complete response’’
to ITP patients who achieved platelet counts .100 3 109/l
spontaneously or after treatment [15–18]. In fact, the decision
to deﬁne as ITP a platelet count between 1003 109/l and 150
3 109/l in an otherwise healthy individual is not supported by
recent epidemiological studies. The reference values for
platelet counts vary somewhat among laboratories, due to
methodology, ethnicity, geographic location, age, etc. Platelet
counts below 150 3 109/l have been found in signiﬁcant
proportions of healthy individuals in different geographical
areas of the same country [12,19]. Age-related physiological
changes are also known to occur, and in a United States
National Health and Nutrition Examination Survey
(NHANES), the reference values for the elderly were found
to be lower than those in younger people [20]. On the other
hand, in this study we have shown that individuals with a
borderline thrombocytopenia represent a heterogeneous
population. Some will develop a more signiﬁcant thrombo-
cytopenia with the characteristics of ITP, others will develop
an autoimmune disease, but the majority will retain a platelet
count between 1003 109/l and 1503 109/l without developing
diseases. Therefore, although there is obviously some degree
of overlapping between the two entities, the identiﬁcation of
borderline thrombocytopenia as being different from ITP
appears on the whole sustainable from a clinical point of
view.
The most frequent event during the initial observation
period as well as during subsequent follow-up was the
development of an autoimmune disorder. The 10-y proba-
bility of developing ITP was 6.9%, whereas that of developing
other autoimmune disorders was 12.0%. Since there was no
follow-up of the control group, we don’t know whether the
study cohort has an increased risk of developing an auto-
immune disorder. Comparative ﬁgures in the general
population are not available, although autoimmune diseases
have been reported to affect approximately 3% of the US
population [5]. Not unexpectedly, in our study most of the
cases of autoimmune disease occurred in women. This
concords with the prevalence statistics of autoimmune
diseases in the general population [21].
The similar prevalence of markers of autoimmunity in the
study population and in the control group simply indicates
that our cohort was not a selected high-risk subset with
regard to these parameters, but does not allow any
assumption to be made about the prognostic value of the
platelet count itself. As a matter of fact, the results of our
study indicate that many cases of autoimmune disease
develop in individuals with a low platelet count who do not
possess ANA, or other conventional markers of autoimmun-
ity. This is in contrast with the conclusions of a recent
retrospective investigation, which implied that autoanti-
bodies are typically present many years before the diagnosis
of systemic lupus erythematosus is made [6]. However, in our
series there were just two cases of systemic lupus erythema-
tosus (both of whom had detectable ANA on study entry), and
in many of the other autoimmune diseases such as psoriatic
arthritis or inﬂammatory bowel disease, there were, in
general, no detectable autoantibodies.
In all but one case, the development of an autoimmune
disorder was diagnosed because the individuals became
symptomatic. Although there were no delays in diagnosis
and treatment, the real impact on prognosis of intensive
follow-up remains to be demonstrated.
It is noteworthy that many cases considered eligible for the
study had chronic thyroiditis, as deﬁned by high titers of
TPO-Ab. The relationship between autoimmune thrombocy-
topenia and chronic thyroiditis is a controversial issue
[22,23]. However, the prevalence of chronic thyroiditis in
our series of individuals with borderline thrombocytopenia
(7%) does not seem higher than in the general population
(6.2%), and those with a chronic thyroiditis did not show a
higher risk of developing ITP or other autoimmune disorders
than the other individuals.
Only four cases of myelodysplastic syndrome were diag-
nosed, two of which were during the initial 6-mo observation.
Therefore the ﬁnding of an isolated thrombocytopenia in the
elderly in our series was not associated with myelodysplastic
syndrome in the majority. This is not surprising, because the
reference values for the elderly have been found to be lower
than those in younger people [20].
Coronary heart disease and the other diseases that
occurred during follow-up, do not appear to be linked to
the thrombocytopenia and all patients who developed
coronary heart disease were of advanced age with no evidence
of vasculitis or other systemic autoimmune disorder.
Although the association between immune thrombocytope-
Figure 3. Cumulative Incidence of an Autoimmune Disease Other Than
ITP
The upper and lower lines indicate the 95% confidence limits.
DOI: 10.1371/journal.pmed.0030024.g003
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nia and cancer has been reported in several anecdotal reports
and a few small series [24–26], the existence of a pathogenetic
link between these diseases is not supported by the rarity of
this association.
In conclusion, our study suggests that individuals with a
platelet count between 1003 109/l and 1503 109/l have a 10-y
probability of developing autoimmune disorders of 12%.
Further investigation is required to establish whether this risk
is higher than in the general population and whether an
intensive follow-up of this condition has a positive impact on
prognosis.
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Patient Summary
Background. Platelets come from large cells in the bone marrow called
megakaryocytes (literally, ‘‘cells with large nuclei’’). They help form blood
clots by releasing substances that activate the blood-clotting process
and also by sticking together. Thrombocytopenia (literally, a ‘‘lack of
thrombocytes’’—another word for platelets) is the condition when the
number of platelets in the blood drops below the normal range, the
lower limit of which is around 150 billion in each liter of blood (written as
150 3 109/l). People with thrombocytopenia may have abnormal
bleeding. What is not clear is whether people who have platelet counts
that are only slightly lower than normal—between 1003109/l and 1503
109/l—will go on to develop thrombocytopenia, or any other disease.
Why Was This Study Done? The researchers wanted to look at people
who had been discovered to have platelet counts between 1003 109/l
and 1503 109/l (borderline thrombocytopenia) and see what happened
to their platelet counts over a long period of time, and whether they
developed any diseases.
What Did the Researchers Do and Find? They followed 191 people
who had borderline thrombocytopenia. In 64% of those people, the
platelet count became normal or stayed low with no other illness. Over
10 years, there was a 6.9% chance of thrombocytopenia and a 12%
chance of another autoimmune disorder occurring. Most of the cases of
autoimmune disease occurred in women.
What Do These Findings Mean? Other studies have suggested that
around 3% of the population will develop autoimmune disease. Hence,
having a platelet count just below normal may mean that a person is
more likely to develop such an illness, However, since the authors did
not directly compare this group of patients with a group of people with
normal platelet counts, it is not possible to be sure. So it is not yet clear
how worthwhile it is to closely follow people with platelet counts just
below normal, and more information is needed on other people with
borderline thrombocytopenia.
Where Can I Get More Information Online? MedlinePlus has links to
pages of information on thrombocytopenia:
http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), which is part of the US National Institutes of Health, has a
page of information on thrombocytopenia:
http://www.niddk.nih.gov/health/hematol/pubs/itp/itp.htm
National Guideline Clearinghouse (NGC), a public resource for evidence-
based clinical practice guidelines, has a page of information on
thrombocytopenia:
http://www.guideline.gov/summary/summary.aspx?ss¼15&doc_
id¼7266&nbr¼4328
Dr. Robert McMillan, an expert in platelet disorders, has developed a
Web site dedicated to adult chronic immune thrombocytopenic purpura:
http://www.scripps.edu/itp
The ITP Support Association, a UK registered charity that aims to
promote and improve the general welfare of patients, and the families of
patients, has some pages of information on ITP:
http://www.itpsupport.org.uk
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